The disclosure relates to spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines of formula (I) with BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of Alzheimer&rsquo；s disease and type 2 diabetes. Example compounds include: (R)-N-(2&rsquo；-amino-5&rsquo；,5&rsquo；-difluoro-2,3,5&rsquo；,6&rsquo；-tetrahydrospiro[indene-1,4&rsquo；-[1,3]oxazine]-6-yl)-5-cyanopicolinamide, (R)-6-(5-chloropyridin-3-yl)-5&rsquo；,5&rsquo；-difluoro-5&rsquo；,6&rsquo；-dihydrospiro[chroman-4,4&rsquo；-[1,3]oxazin]-2&rsquo；-amine, (R)-N-(2&rsquo；-amino-5&rsquo；,5&rsquo；-difluoro-2,3,5&rsquo；,6&rsquo；-tetrahydrospiro[indene-1,4&rsquo；-[1,3]oxazine]-6-yl)-5-chloropicolinamide, and (R)-N-(2&rsquo；-amino-5&rsquo；,5&rsquo；-difluoro-2,3,5&rsquo；,6&rsquo；-tetrahydrospiro[indene-1,4&rsquo；-[1,3]oxazine]-6-yl)-5-fluoropicolinamide.
